Drug Interactions between clonazepam and Viberzi
This report displays the potential drug interactions for the following 2 drugs:
- clonazepam
- Viberzi (eluxadoline)
Interactions between your drugs
No interactions were found between clonazepam and Viberzi. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
clonazepam
A total of 532 drugs are known to interact with clonazepam.
- Clonazepam is in the following drug classes: benzodiazepine anticonvulsants, benzodiazepines.
-
Clonazepam is used to treat the following conditions:
- Anxiety (off-label)
- Benzodiazepine Withdrawal (off-label)
- Bipolar Disorder (off-label)
- Borderline Personality Disorder (off-label)
- Burning Mouth Syndrome (off-label)
- Chronic Myofascial Pain (off-label)
- Cluster-Tic Syndrome (off-label)
- Epilepsy
- Hyperekplexia (off-label)
- Insomnia (off-label)
- Lennox-Gastaut Syndrome
- Meniere's Disease
- Migraine Prevention (off-label)
- Night Terrors (off-label)
- Obsessive Compulsive Disorder (off-label)
- Panic Disorder
- Periodic Limb Movement Disorder (off-label)
- Primary Orthostatic Tremor (off-label)
- Restless Legs Syndrome (off-label)
- Seizure Prevention
- Seizures
- Sleep Paralysis (off-label)
- Temporomandibular Joint Disorder (off-label)
Viberzi
A total of 214 drugs are known to interact with Viberzi.
- Viberzi is in the drug class peripheral opioid receptor mixed agonists/antagonists.
- Viberzi is used to treat the following conditions:
Drug and food interactions
eluxadoline food
Applies to: Viberzi (eluxadoline)
CONTRAINDICATED: Consumption of more than 3 alcoholic beverages per day may increase the risk of acute pancreatitis during treatment with eluxadoline. Pancreatitis has been reported rarely during clinical trials of eluxadoline, and may or may not be related to sphincter of Oddi spasm.
ADJUST DOSING INTERVAL: High-fat meals may reduce the oral bioavailability of eluxadoline. In 28 healthy volunteers, administration of a single 100 mg dose of eluxadoline with a high-fat meal (approximately 800 to 1000 total calories, 50% from fat) decreased eluxadoline peak plasma concentration (Cmax) and systemic exposure (AUC) by 50% and 60%, respectively, compared to administration in the fasted state. There was no significant effect on the time to peak concentration (Tmax). The clinical relevance of this interaction is unknown. It should be noted that phase 3 clinical trials were conducted under fed conditions.
MANAGEMENT: Chronic or acute excessive use of alcohol should be avoided during treatment with eluxadoline. Alcoholism, alcohol abuse, alcohol addiction, and consumption of more than 3 alcoholic beverages per day are considered contraindications to the use of eluxadoline. The product labeling recommends taking eluxadoline with food. Patients should be advised to stop taking eluxadoline and seek medical attention if they experience potential symptoms of pancreatitis such as persistent nausea, vomiting, abdominal tenderness, and upper abdominal pain, especially that which is made worse after eating or radiates to the back or shoulders.
References (1)
- (2015) "Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc.
clonazePAM food
Applies to: clonazepam
GENERALLY AVOID: Acute ethanol ingestion may potentiate the CNS effects of many benzodiazepines. Tolerance may develop with chronic ethanol use. The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition. Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.
MANAGEMENT: Patients should be advised to avoid alcohol during benzodiazepine therapy.
References (7)
- MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM (1977) "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol, 11, p. 345-9
- Whiting B, Lawrence JR, Skellern GG, Meier J (1979) "Effect of acute alcohol intoxication on the metabolism and plasma kinetics of chlordiazepoxide." Br J Clin Pharmacol, 7, p. 95-100
- Divoll M, Greenblatt DJ, Lacasse Y, Shader RI (1981) "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl), 73, p. 381-3
- Juhl RP, Van Thiel DH, Dittert LW, Smith RB (1984) "Alprazolam pharmacokinetics in alcoholic liver disease." J Clin Pharmacol, 24, p. 113-9
- Ochs HR, Greenblatt DJ, Arendt RM, Hubbel W, Shader RI (1984) "Pharmacokinetic noninteraction of triazolam and ethanol." J Clin Psychopharmacol, 4, p. 106-7
- Staak M, Raff G, Nusser W (1979) "Pharmacopsychological investigations concerning the combined effects of dipotassium clorazepate and ethanol." Int J Clin Pharmacol Biopharm, 17, p. 205-12
- Nichols JM, Martin F, Kirkby KC (1993) "A comparison of the effect of lorazepam on memory in heavy and low social drinkers." Psychopharmacology (Berl), 112, p. 475-82
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.